anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
OBJECTIVE: We aimed to assess the ability of semiautomated electric source imaging (ESI) from long-term video-electroencephalographic (EEG) monitoring (LTM) to determine the epileptogenicity of temporopolar encephaloceles (TEs) in patients with temporal lobe epilepsy.
METHODS: We conducted a retrospective study involving 32 temporal lobe epilepsy patients with TEs as potentially epileptogenic lesions in structural magnetic resonance imaging scans. Findings were validated through invasive intracerebral stereo-EEG in six of 32 patients and postsurgical outcome after tailored resection of the TE in 17 of 32 patients. LTM (mean duration = 6 days) was performed using the 10/20 system with additional T1/T2 for all patients and sphenoidal electrodes in 23 of 32 patients. Semiautomated detection and clustering of interictal epileptiform discharges (IEDs) were carried out to create IED types. ESI was performed on the averages of the two most frequent IED types per patient, utilizing individual head models, and two independent inverse methods (sLORETA [standardized low-resolution brain electromagnetic tomography], MUSIC [multiple signal classification]). ESI maxima concordance and propagation in spatial relation to TEs were quantified for sources with good signal quality (signal-to-noise ratio > 2, explained signal > 60%).
RESULTS: ESI maxima correctly colocalized with a TE in 20 of 32 patients (62.5%) either at the onset or half-rising flank of at least one IED type per patient. ESI maxima showed propagation from the temporal pole to other temporal or extratemporal regions in 14 of 32 patients (44%), confirming propagation originating in the area of the TE. The findings from both inverse methods validated each other in 14 of 20 patients (70%), and sphenoidal electrodes exhibited the highest signal amplitudes in 17 of 23 patients (74%). The concordance of ESI with the TE predicted a seizure-free postsurgical outcome (Engel I vs. >I) with a diagnostic odds ratio of 2.1.
SIGNIFICANCE: Semiautomated ESI from LTM often successfully identifies the epileptogenicity of TEs and the IED onset zone within the area of the TEs. Additionally, it shows potential predictive power for postsurgical outcomes in these patients.
The radiolabeled Tc-99 colloid or phytate (500 Mbq) will be injected into the primary tumor 2 hours before surgery. A localized scintiscan will then be performed to confirm the radiolabeling of the sentinel node before surgery and for documentation. Isosulphan blue dye will be injected subdermal (0.5ml) over the tumor and intraparenchymal (3-4ml) towards the axilla 10-15mins before incision.
All patients will undergo sampling of pancreatic masses using the Acquire EUS Biopsy Device. Both needles will be used, but the needle to be used first will be based on randomization. A minimum of at least one pass and a maximum of 8 passes will be performed using both needle types.
Systems and methods for out-of-distribution detection of nodes in a graph includes collecting evidence to quantify predictive uncertainty of diverse labels of nodes in a graph of nodes and edges using positive evidence from labels of training nodes of a multi-label evidential graph neural network. Multi-label opinions are generated including belief and disbelief for the diverse labels. The opinions are combined into a joint belief by employing a comultiplication operation of binomial opinions. The joint belief is classified to detect out-of-distribution nodes of the graph. A corrective action is performed responsive to a detection of an out-of-distribution node. The systems and methods can employ evidential deep learning.
The invention discloses a preparation method of water soluble active collagen. The preparation method comprises the following steps: extraction of acid-soluble natural collagen; purification of acid-soluble natural collagen; preparation of a water soluble active collagen coarse product; and preparation of the water soluble active collagen. The invention further discloses an epidermis repair growth factor liquid containing the water soluble active collagen prepared by the preparation method. According to the technical field of the water soluble active collagen disclosed by the invention, wastes are turned to wealth, so that the value of umbilical cord and placenta is utilized and developed to the maximum extent. The water soluble active collagen is extracted from a healthy human placenta and/or umbilical cord, is easy to absorb and avoids immunoreaction caused by allogenic materials. The water soluble active collagen is free from external factors and does not contain chemical additives, so that the water soluble active collagen is closer to nature when in use, and the combined effect is best. By taking the water soluble active collagen serving as a main raw material can be matched with various cell factors and plant essences, so as to achieve the effects of repairing and regenerating skin, preventing sensitivity, diminishing inflammation, reducing wrinkles and lightening stains, avoiding adverse reaction and achieving good safety.
Patients with brain metastases will be enrolled in one of three dose levels based on tumor size. For tumor size of 3 cm or less (maximum diameter in any dimension), doses of 47.5Gy, 52.5Gy, and 54.5Gy will be tested. For tumor size of greater than 3 cm (maximum diameter in any dimension), doses of 42.5Gy, 47.5Gy, and 52.5Gy will be tested.
Diabetes and its complications pose a substantial physical, psychological and financial burden on the large number of racial/ethnic minorities and other socioeconomically deprived persons with diabetes. However, self-management goals are often not met in racial/ethnic minorities and in populations with fewer socioeconomic resources. In response, our research team has developed a novel "health coaching" intervention to promote diabetes self-management in the community. Health coaching is based on Control Systems Theory and helps patients to: 1) identify problems in self-care behaviors; 2) create dynamic plans for correcting these issues; and, 3) learn to navigate the complexities of everyday life and to achieve clinically and personally desirable outcomes. The primary innovation of the present project is that first-year medical students are trained to serve as the health coaches, and are participating in the study Coaching for Control (STU00069506). The objective of our pilot study is to test whether 20 patients from five Northwestern Medicine primary care practice groups (two in the Austin community, two at Northwestern Memorial Hospital and one at Norwegian American Hospital) enrolled in the "Coaching for Control" intervention experience favorable changes in clinical and behavioral outcomes after 16 weeks as compared with an equal number of patients from those same clinics who are not enrolled in the program. We will use a non-randomized trial design to carry out the following aims: 1. Determine whether patients with diabetes who participate in the "Coaching for Control" behavioral intervention program (i.e., the intervention arm) have lower hemoglobin A1c (HbA1c) after four months than patients who do not participate in the program (i.e., the control arm). 2. Determine whether diabetes patients in the intervention arm report higher task-related self-efficacy for initiating and maintaining recommended diabetes self-care behaviors than participants in the control arm. We hypothesize that participants in the intervention arm will have more favorable HbA1c and report higher self-efficacy for diabetes self-care behaviors than participants in the control arm. Secondary objectives are to test whether these changes persist 8 months after the program ends and to test whether we observe changes in additional clinical measures such as blood pressure, waist circumference, and in self-reported health behaviors such as medication adherence, self-care behaviors, physical activity and diet. Process evaluations through focus groups and interviews with participants will allow us to refine our intervention. The translational aspects of our proposal include the application of a proven intervention to promote diabetes self-care in a community setting that includes adults at high risk for diabetes complications. Findings from the present pilot study will be used to justify expansion of the study to a larger group of community members so that we can carry out a larger randomized trial of efficacy.
PROBLEM TO BE SOLVED: To provide a target structure for diagnosis and treatment of cancer.SOLUTION: A pharmaceutical composition comprising a preparation which: (I) inhibits expression or activity of a tumor-associated antigen; and/or (II) has tumor inhibitory activity and is selective for cells which express the tumor associated antigen or which exhibit abnormal expression thereof; and/or (III) selectively increases the amount of a complex of an MHC molecule and tumor associated antigen or a part thereof when administered. The tumor associated antigen has a sequence encoded by nucleic acid selected from (a)-(d). (a) a nucleic acid comprising a specific nucleic acid sequence, or a part or derivative thereof. (b) a nucleic acid which hybridizes with the nucleic acid of (a) under stringent conditions. (c) a degenerate nucleic acid associated with the nucleic acid of (a) or (b). (d) a nucleic acid complementary to the nucleic acid of (a), (b) or (c).SELECTED DRAWING: None
Patients with localized high-risk prostate cancer were treated with 4 cycles (16 weeks) of continuous weekly paclitaxel at 80 mg/m\^2 intravenously with estramustine at 280 mg orally 3 times a day for 5 days a week and carboplatin (area under the curve of 6) on Day 1 of every cycle followed by 3-dimensional conformal or intensity-modulated radiotherapy (total dose of 77.4 gray \[Gy\] in 1.8-Gy fractions). All patients received androgen deprivation therapy with either goserelin acetate at 3.6 mg subcutaneously or leuprolide acetate at 7.5 mg intramuscularly monthly for 6 months starting at Day 1 of therapy.
PROBLEM TO BE SOLVED: To obtain a substrate extract that is useful as a medicine for treating human diseases caused by viruses, for example, influenza or common cold, by cutting a mixture of fruits and the like of a tree (Sambucus nigara L.) into tiny pieces, extracting them with boiled water and filtering the extract by a specific method. SOLUTION: (A) An even mixture of 66-72 wt.% of the fruits of the elder tree, 11-14 wt.% of the barks of branches, and 17-20 wt.% of the leaves is cut at their wood parts into tiny pieces of <=1 cm size. (B) 70-90 grams, preferably 15-85 grams of the component A per liter of the component B are added to boiled water and heated, preferably for 45 minutes to decoct the component A and the heating is stopped. Then, decoction product is subjected to the first decantation, the second filtration through a sieve to remove solid pieces to obtain the substrate extract. This extract is useful as a substrate material for medicines, for example, nasal and throat congestion, non-bacterial throat inflammation, or laryngitis, and the diseases caused by viruses that bear ribonucleic acid as an genetic material.  This extract is used as a substrate material for medicines, for example, tablets, powder and the like.
A QDOT® 3.5-mm open-irrigated contact force-sensing RF ablation catheter (Biosense Webster, Inc., Irvine, CA, USA) will be used. In this group vHPSD (90W) will be performed. This power settings will be used for all ablation points.
EBUS-TBNA is an important minimally invasive tool for the diagnosis of mediastinal and hilar lymphadenopathy. The investigators will explore the performance of two kinds of needles and different methods to obtain tissues via EBUS-TBNA in the study. The study is designed as a prospective, single-center, randomized controlled trial, 600 patients will be expected to enroll in the study and randomly assigned to two groups, the 22G-ProCore group and the 22G-Standard group. The primary aim is to compare the diagnostic yields of the two types of needles. The secondary endpoint is to assess the quality of histologic specimen. Meanwhile, stylet slow-pull or negative suction techniques and different agitations (10, 20, 30 times) that each pass includes will be evaluated in the study as well.
Patients receive PEG-proline-interferon alpha-2b SC on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Recovery after caesarean section is a complex process, depending on the characteristics of the patient and the anaesthesia. Scales for measuring the quality of post-operative recovery have been developed. Ciechanowicz et al. developed and validated a postpartum recovery score for women with a caesarean section: the ObsQoR-11. This multidimensional scale is a questionnaire of 11 items evaluating: moderate pain, severe pain, nausea and vomiting, feeling of discomfort, shivering, feeling of comfort, ability to mobilize, ability to carry the newborn, ability to feed, ability to groom alone, and finally feeling of self-control. The investigators aimed to validate the translated version of the Turkish ObsQoR-11 scale.
The invention belongs to the technical field of genetic engineering vaccines, and particularly relates to a avian (A-type) subunit vaccine for chicken nasal tracheal and a preparation method and application thereof. The subunit vaccine comprises OMA87 protein with the size of 97.15kD, the gene sequence is shown as SEQ ID No.4, and the amino acid sequence is shown as SEQ ID No. 5. After induced expression, OMA87 protein is purified and detoxified, and a semi-finished antigen with the purity of more than 50% and the endotoxin content of 2500EU/mL or less is obtained. And (3) emulsifying by using a white oil adjuvant to prepare a qualified OMA87 protein subunit vaccine, namely the avian infectious bursal disease subunit vaccine. The vaccine has good safety when being used for immunizing broiler chickens and laying hens, and the generated antibody level is high and long in duration, so that a method for preventing the infection of the broiler chickens and the laying hens by the avian bacillus rhinotracheae is provided.
A stable fixed dose oral pharmaceutical formulation is provided. The formulation contains at least one anti-infective agent and at least one susceptible microorganism as active ingredients. At least one of the active ingredients is coated to provide a protective barrier around the active ingredient, the active ingredients being contained in a single pharmaceutical formulation. The formulation may be a tablet, a capsule, or a powder which may be made into a stable liquid. The protective barrier protectis the susceptible micro-organism from the effect of the anti-infective agent to maintain the susceptible micro-organism in a viable form for a period of at least three months. The anti-infective agent can be an antibiotic such as an amoxycillin and the microorganism can be  Lactobacillus acidophilus.
In this study, investigators will choose male and female subjects aged between 35 and 79 years old with mild to moderate essential hypertension. At first 2 weeks, all patients will use felodipine 5mg daily. If the blood pressure dosen't meet the target (140/90mmHg), they will be randomized into metoprolol, lisinopril or hydrochlorothiazide combination groups for another 4 weeks therapy. After that, if the blood pressure has still not met the target, up-titrate the felodipine into 10mg, followed by a 4 weeks therapy. And if the blood pressure is still not met the target after that, up-titrate the combine drugs into maximum dosage. The whole treatment duration is 14 weeks.

The primary outcome is to evaluate the percentage of subjects reaching blood pressure target (defined as \< 140 / 90 mmHg) after 14 weeks treatment with felodipine sustained release in combination with metoprolol, lisinopril or hydrochlorothiazide.
The invention relates to the technical field of medicines. Conventional cancer therapies such as radiotherapy, chemotherapy, biological factor therapy and the like lack targeting, while non-specific toxic and side effects of toxin protein and other problems exist in immunotoxin therapy. In the invention, a maytansine drug derivative and an antibody resisting ErbB2/Neu/HER2 are coupled through a connexon. The connexon is insensitive to acid and peptidase cathepsin, and is free of disulfide bond, thus being able to provide stability before a conjugate enters a cell. For example, in systemic circulation, the conjugate can be prevented from untimely degrading and releasing toxic drugs, so that the toxic effects of drugs can be minimized. The conjugate can combine with the tumor cell surface ErbB antigen and undergoes endocytosis. Drugs in the conjugate generate cytotoxicity to an antigen expressed cell, inhibit cell growth or prevent the recurrence of antigen positive cancer. The invention also provides a preparation method and use of the conjugate.
The invention provides a probe for modifying protein lysine residue, which has the structural formula shown as follows: the invention also provides a preparation method of the probe for modifying protein lysine residues. The invention also provides application of the probe in preparation of lysine-containing protein for enriching tumor tissues. The invention also provides an improved pyridinium probe and a preparation method thereof. The invention also provides a biosensor modified by the improved pyridinium probe. The invention also provides the use of the improved pyridinium probe described above in the preparation of a biosensor. The invention also provides application of the biosensor in preparation of lysine detection products. The invention solves the problem of low efficiency of the traditional lysine coupling strategy, and provides a feasible detection strategy based on a biosensor for detecting lysine in blood.
Mild ovarian stimulation regimen using the endogenous FSH production by starting treatment on day 5 of the menstrual cycle with 150 IU / d recFSH with GnRH antagonist co treatment starting on day 6. As soon as two follicles reach 12 mm, treatment is continued with 200 IU / d rec hCG.
Older adults who participated in a group exercise program using the developed mat and software three times per week for six weeks (18 sessions) for a pilot study and twelve weeks (36 sessions) for a main study took part in the pre-post tests. The frequency and duration can be adjusted to twice per week for nine weeks (18 sessions) for a pilot study or twice per week for sixteen weeks (32 sessions) for a main study to accommodate the availability of participants and the spaces in the community center.
1. Technical Result Increase in effectiveness of treatment of diseases caused by bacterial infections.                 2. Essence Compound is presented by the formula wherein R has the meaning of a substituted aryl group of formula (II) provided in the description, wherein substituents a, b, c, d and e are the same or different and at least one of them has the meaning of halo or a (C1-C6)haloalkoxy, whereas the remaining ones selected from the group containing hydrogen, halogen, a(C1-C6)alkyl or a(C1-C6)alkoxy and x is oxygen or sulfur; a process for the preparation, pharmaceutical composition comprising them and the use of these pharmaceutical compositions for the treatment or prevention of bacterial infections.         3. Field of Application Medicine.
PURPOSE: To compare dominant and non-dominant hand phacoemulsification surgery outcomes.
METHODS: This retrospective, single-center study included 300 patients who underwent phacoemulsification surgery by a single, right-handed surgeon. The patients were divided into two groups according to whether the surgeon used his dominant or non-dominant hand during surgery. Right eye operations were performed with the right hand, and left eye operations were performed with the left hand. Detailed ophthalmological examinations were performed on all patients preoperatively and postoperatively. Intraoperative phacoemulsification parameters, the presence of intraoperative and postoperative complications, postoperative refractive errors, visual acuity, and surgically induced astigmatism values were compared between the groups.
RESULTS: There were 171 patients in the dominant hand phacoemulsification group and 129 patients in the non-dominant hand phacoemulsification group. The distributions of age, gender, systemic diseases, and lens opacification were similar between the groups (p>0.05, for all). No statistically significant difference was observed between the two groups in terms of total operation time, phaco power, ellips fx, or ultrasonic time (p>0.05, for all). There was also no significant difference in relation to intraoperative and postoperative complication distributions, postoperative third-month refractive errors, visual acuity, or surgically induced astigmatism values (p>0.05, for all).
CONCLUSION: This study demonstrated that cataract surgery performed by a single surgeon can be effectively and safely performed using both hands on patients in a real operating theater environment. More objective results can be obtained with surgeries performed by a larger number of experienced surgeons.
The present invention relates to an autonomic-replication-type carrier in human's liver-cancer cell specific viruses and usage thereof. The autonomic-replication-type carrier is composed of a liver-cancer cell specific promotor namely an alpha-fetoprotein gene promotor, an EB virus plasmid type replicon, a trans-acting factor, a eukaryotic cell resistance selection mark, and an escherichia coli plasmid skeleton with an escherichia coli replicon and an ampicillin resistance gene. The autonomic-replication-type carrier can lead an exogenous gene to be inputted into a cell for autonomic replication in a non-virus infection mode and can only have specific expression in liver-cancer cells which generate alpha fetoprotein. Compared with a mode that a recombined virus particle is directly used for directly leading cells to be infected, the safety is higher. The present invention is mainly used for the gene therapy of a primary liver cancer. Tumour cells can be killed in a selectivity mode, and the functions of normal cells can not be influenced.